Is HER2 the New NECTIN4 in Advanced Urothelial Cancer?
- PMID: 38825408
- DOI: 10.1016/j.euf.2024.05.018
Is HER2 the New NECTIN4 in Advanced Urothelial Cancer?
Abstract
Antibody-drug conjugates have transformed treatment for urothelial cancer (UC). Enfortumab vedotin is the new standard of care in the first-line setting for advanced UC. A personalised approach targeting HER2 in UC is currently being explored.
Crown Copyright © 2024. Published by Elsevier B.V. All rights reserved.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous